Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Diffuse, large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Identifying reliable prognostic markers is crucial for managing DLBCL patients.
• Interleukin-10 (IL-10) is a cytokine with known roles in immune regulation and cancer.

Purpose of the Study:

• To investigate the correlation between plasma interleukin-10 (IL-10) levels and prognosis in diffuse, large B-cell lymphoma (DLBCL) patients.
• To determine if IL-10 levels can serve as a predictive biomarker for treatment response and survival outcomes in DLBCL.

Main Methods:

• Plasma IL-10 levels were measured at diagnosis in 157 DLBCL patients.
• Association of IL-10 levels with clinical-pathological features and treatment outcomes was analyzed.
• Statistical methods included odds ratios (OR) and confidence intervals (CI) to assess significance.

Main Results:

• 35 (22%) patients had detectable plasma IL-10 levels (> 5 pg/mL).
• Detectable IL-10 was associated with adverse prognostic factors: older age, poor performance status, advanced stage, bulky disease, elevated LDH and beta2-microglobulin, anemia, low albumin, and B symptoms.
• Detectable IL-10 levels correlated with lower complete remission rates (OR=0.23), shorter progression-free survival (OR=2.5), and shorter overall survival (OR=3.0).

Conclusions:

• Elevated plasma IL-10 levels are confirmed as a significant indicator of adverse disease features in DLBCL.
• Detectable IL-10 is strongly associated with poor prognosis, including reduced CR rates and shorter PFS and OS.
• Plasma IL-10 concentration may serve as a valuable biomarker for assessing DLBCL disease activity and predicting patient outcomes.